ngshrd | 906
HRD Assay
Keywords:
BRCA1
BRCA2
BRCAness
GIS
Genomic Instability Score
HRD
HRR
Homologous Recombination Deficiency
MyChoice
Myriad
Next Generation Sequencing
Next-Generation Sequenzierung
Ovarian cancer
Ovarian carcinoma
Status
| Hint |
Mutations in >50 genes associated with BRCAness (incl. BRCA1, BRCA2, PALB2) and evaluation of the Genomic Instability Score (GIS)(TruSight Oncology 500 HRD powered by Myriad) To order this analysis, please contact us via contact@viollier.ch or 0848 121 121. This analysis may result in excess information. This will be communicated, unless it is noted otherwise when placing the order. Since in rare cases there may also be indications of hereditary changes, the GUMG shall arrange for the patient to be informed accordingly (see www.viollier.ch/en/SGMG_consent). Tarification: according to Tarmed
|
|---|---|
| Duration | 14 days |
| Frequency | 2 x per week |
| Method | Next Generation Sequencing |
Price/Rate
| Price |
Price
CHF 0.00
|
|---|---|
| Rate |
Rate
0.00 TP
|
